image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Events
November 30, 2021 at 11:30 AM EST
Piper Sandler 33rd Annual Virtual Healthcare Conference
November 16, 2021 at 3:20 PM EST
Stifel 2021 Virtual Healthcare Conference
October 27, 2021 at 8:30 AM EDT
Discussion of Initial NX-2127 Phase 1a PK/ PD Data

Corporate Profile

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents.
 

Data Provided by Refinitiv. Minimum 15 minutes delayed.